Patients with hypereosinophilic syndrome (HES) display a very heterogeneous clinical picture ranging from asymptomatic cases to very aggressive forms. We report a 38-year-old woman with progressive HES who developed severe myelofibrosis and was treated by allogeneic stem cell transplantation, using peripheral blood (PBSCT) instead of bone marrow as the source of progenitor cells, after conditioning with cytoxan and busulphan. To the best of our knowledge, this is the first case of HES with myelofibrosis treated with PBSCT. The patient remains alive 8 months post-PBSCT, and bone marrow fibrosis has significantly decreased following transplantation. Bone Marrow Transplantation (2000) 25, 217-218. Keywords: hypereosinophilic syndrome; allogeneic peripheral blood stem cell transplantation; myelofibrosis Hypereosinophilic syndrome (HES) is a rare heterogeneous group of disorders whose common denominator is a persistent eosinophilia without detectable causes.
Hypereosinophilic syndrome (HES) is a rare heterogeneous group of disorders whose common denominator is a persistent eosinophilia without detectable causes. 1, 2 Cases of HES are generally associated with visceral involvement, considered to be related to tissue eosisnophil infiltration. 1, 2 While some cases are regarded as non-malignant, others are considered as myeloproliferative disorders, which may evolve into leukemia. 1, 2 Recently, Sadoun et al 3 reported a patient with HES and advanced myelofibrosis who underwent allogeneic bone marrow transplantation.
We describe a similar case, also characterized by the presence of marked myelofibrosis, but we used peripheral blood instead of bone marrow stem cells as the source of progenitor cells for transplantation.
Case report
A 38-year-old woman was diagnosed with hypereosinophilic syndrome in January 1993 following a routine examination that revealed an increase in blood eosinophils (×10 9 /l) with normal hemoglobin and platelets. There was no evidence of parasitic, allergic or other recognized causes of eosinophilia. Since she was asymptomatic, no treatment was given. The blood eosinophil count remained unchanged until February 1997. At this time she complained of fever, abdominal pain, diarrhea, cough, diffuse myalgias and hypoesthesia of the left heel. Physical examination revealed splenomegaly, with the spleen 10 cm below the costal margin. Echocardiogram did not show cardiac damage. Broncho-alveolar lavage was normal. White blood cells (WBC) were 34 × 10 9 /l with 67% eosinophils, 13% neutrophils, 11% basophils, 5% lymphocytes and 2% monocytes. The hemoglobin (Hb) was 11.4 g/dl and platelet count 258 × 10 9 /l. Leukocyte alkaline phosphatase score was normal. Vitamin B12 and serum alkaline phosphatase levels were Ͼ2000 pmol/l (normal: 120-680) and 274 UI/l (normal: Ͻ260), respectively. IgE level was 443 UI/l (normal: Ͻ100). A search for allergic, neoplastic or connective tissue diseases and tissue invasive helminths was negative. Bone marrow aspirate was hypercellular with a marked increase of mature eosinophils but no blast cells. Karyotypic analysis of bone marrow cells showed 46XX. Philadelphia chromosome as well as BCR-ABL was negative both for FIS and PCR. She was treated with corticosteroids and hydroxyurea (HU) with absence of response and interferon alpha was added, but the persistent eosinophilia with general symptomatology did not resolve but improved slightly.
In July 1998, the patient was admitted with fever. Echocardiogram showed mild mitral regurgitation without damage to the atrio-ventricular valves and without cardiac failure. Electromyogram showed no peripheral neuropathy. The WBC count was 19.8 × 10 9 /l with 64% eosinophils. Hb was 8.8 g/dl and platelets 87 × 10 9 /l. Bone marrow biopsy was hypercellular and showed marked myelofibrosis. Cytogenetic analysis remained normal. Due to clinical deterioration, progressive anemia and thrombocytopenia, the young age of the patient and the availability of an HLAidentical sibling, an allogeneic PBSCT was performed in September 1998. The donor was sex and ABO matched. 
Discussion
Within the diagnosis of HES a very heterogeneous spectrum of clinical pictures can be found, ranging from asymptomatic cases to very aggressive forms. [4] [5] [6] [7] In fact it is very difficult to determine whether HES is the result of an autonomous uncontrolled growth-myeloproliferative (MPD) or if it is secondary to overproduction of eosinophilopoietic cytokines produced by a T cell clone. 8 Some reports state that HES/MPD can be identified by the following characteristics: elevated B12 level, abnormal leukocyte alkaline phosphatase score, splenomegaly, cytogenetic abnormalities, myelofibrosis anaemia, myeloid dysplasia and basophilia.
1 These latter cases usually show a progressive course in spite of treatment with hydroxyurea, corticosteroids and IFN. Following 4 years of stable disease, the patient was referred to our institution due to the presence of general symptoms and progressive eosinophilic that indicated disease progression. Although she was initially treated with hydroxyurea, corticosteroids and IFN, no response occurred. Moreover, anemia and thrombocytopenia appeared together with marked bone marrow fibrosis. Due to the patient's age and the existence of an HLA identical sibling, she was considered for allogeneic transplant. To the best of our knowledge, only four cases of HES who underwent allogeneic stem cells transplantation have been reported (Table 1) . Two of these four patients are alive and disease-free, one is alive in relapse and the other has died. According to our current transplant policy we used peripheral blood (PB) stem cells instead of BM as the source of stem cells. As reported, the patient rapidly engrafted with only mild acute GVHD and no chronic GVHD. Moreover, as with the case reported by Sadoun et al, 3 fibrosis has almost disappeared following transplant.
In summary, PBSCT should be considered as an alternative therapeutic approach in aggressive forms of HES. Whether or not PB is associated with less toxicity than BM transplants in these patients warrants further investigation with a larger number of patients.
